Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 168

1.

DNA methylation profiling of synovial fluid FLS in rheumatoid arthritis reveals changes common with tissue-derived FLS.

Glossop JR, Haworth KE, Emes RD, Nixon NB, Packham JC, Dawes PT, Fryer AA, Mattey DL, Farrell WE.

Epigenomics. 2015;7(4):539-51. doi: 10.2217/epi.15.15.

PMID:
26111028
2.

Genome-wide DNA methylation profiling in rheumatoid arthritis identifies disease-associated methylation changes that are distinct to individual T- and B-lymphocyte populations.

Glossop JR, Emes RD, Nixon NB, Haworth KE, Packham JC, Dawes PT, Fryer AA, Mattey DL, Farrell WE.

Epigenetics. 2014 Sep;9(9):1228-37. doi: 10.4161/epi.29718.

3.

Epigenome-wide profiling identifies significant differences in DNA methylation between matched-pairs of T- and B-lymphocytes from healthy individuals.

Glossop JR, Nixon NB, Emes RD, Haworth KE, Packham JC, Dawes PT, Fryer AA, Mattey DL, Farrell WE.

Epigenetics. 2013 Nov;8(11):1188-97. doi: 10.4161/epi.26265.

PMID:
24005183
4.

Biology of subjectivity in chronic diseases.

Dawes PT, Ryan S, Jorsh M, Mattey DL.

Rheumatology (Oxford). 2013 Oct;52(10):1733-4. doi: 10.1093/rheumatology/ket142. No abstract available.

5.

Association of circulating levels of MMP-8 with mortality from respiratory disease in patients with rheumatoid arthritis.

Mattey DL, Nixon NB, Dawes PT.

Arthritis Res Ther. 2012 Oct 2;14(5):R204. doi: 10.1186/ar4042.

8.
9.

Influence of variations across the MMP-1 and -3 genes on the serum levels of MMP-1 and -3 and disease activity in rheumatoid arthritis.

Chen Y, Nixon NB, Dawes PT, Mattey DL.

Genes Immun. 2012 Jan;13(1):29-37. doi: 10.1038/gene.2011.46.

PMID:
21753786
10.
11.

Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.

Mattey DL, Dawes PT, Hassell AB, Brownfield A, Packham JC.

J Rheumatol. 2010 Oct;37(10):2021-4. doi: 10.3899/jrheum.100050.

PMID:
20682674
12.

Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study.

Ƙstergaard M, Baslund B, Rigby W, Rojkovich B, Jorgensen C, Dawes PT, Wiell C, Wallace DJ, Tamer SC, Kastberg H, Petersen J, Sierakowski S.

Arthritis Rheum. 2010 Aug;62(8):2227-38. doi: 10.1002/art.27524.

13.

Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis.

Mattey DL, Brownfield A, Dawes PT.

J Rheumatol. 2009 Jun;36(6):1180-7. doi: 10.3899/jrheum.081096.

PMID:
19447930
14.
15.

The overall status in rheumatoid arthritis (OSRA) measure--further evidence to support its use in clinical practice.

Harrison MJ, Hassell A, Dawes PT, Scott DL, Knight SM, Davis MJ, Mulherin D, Symmons DP.

Rheumatology (Oxford). 2007 May;46(5):849-55.

17.
19.

Anemia in rheumatoid arthritis: association with polymorphism in the tumor necrosis factor receptor I and II genes.

Glossop JR, Dawes PT, Hassell AB, Mattey DL.

J Rheumatol. 2005 Sep;32(9):1673-8.

PMID:
16142859
20.
Items per page

Supplemental Content

Loading ...
Support Center